Level Bio AbNGM: LEVBIO

LEVBIO: Q3 2025 saw 5% revenue growth, higher margins, and improved cash flow amid Nordic expansion

· Issued by Level Bio AB

Revenue grew 5% year-over-year in Q3 2025, with gross margin rising to 57% and net loss narrowing. Strong order intake and positive cash flow signal improved performance, while expansion in the Nordics and stable recurring revenues support a positive outlook.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis

Earlier from Level Bio Ab

All Level Bio Ab news releases